GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial ...

The company's vaccine consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein.

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

GSK has reported positive results from its phase II trial for an mRNA seasonal influenza vaccine candidate, showing strong immune responses again ...

The first private spacewalk took place successfully on Thursday, as billionaire businessman Jared Isaacman emerged into the dark vacuum of space from SpaceX’s Dragon capsule, silhouetted against the ...

Delta Air Lines said in an update on Thursday that capacity across the industry was also “moderating” and that its revenue ...

Moderna plans to cut $1.1bn in costs by 2027, pausing and scrapping several R&D programs. See why I think further downside ...

Sanofi's stock has shown volatility, but recent gains are driven by Dupixent's success. Read why I maintain my hold rating on ...

LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive ...